"studyAcronym","studyVersion","studyRationale","studyTitle","id","uuid:ID"
"H2Q-MC-LZZT","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","StudyVersion_1","007d3d5c-5e93-440c-9acc-9836d8738a48"
